PROSPECTUS SUPPLEMENT NO. 3 (to prospectus dated April 5, 2022)

CELLEBRITE DI LTD.

171,729,210 Ordinary Shares 9,666,667 Warrants to Purchase Ordinary Shares 29,666,667 Ordinary Shares Underlying Warrants

This prospectus supplement amends and supplements the prospectus dated April 5, 2022 (the "Prospectus") which forms a part of our Registration Statement on Form F-1, as amended and supplemented, including by Post-Effective Amendment No. 1 thereto (Registration Statement No. 333-259826). This prospectus supplement is being filed to update and supplement the information included in the Prospectus with the GAAP financial statements tables contained in our report of foreign private issuer on Form 6-K, furnished to the Securities and Exchange Commission (the "SEC") on August 11, 2022 (the "Form 6-K"). Such tables from the Form 6-K are attached to this prospectus supplement.

This prospectus supplement updates and supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement.

Our ordinary shares, with par value of NIS 0.00001 per share ("Ordinary Shares"), and warrants to purchase Ordinary Shares ("Warrants") are traded on The Nasdaq Global Market ("Nasdaq") under the symbol "CLBT" and "CLBTW," respectively. The last reported sale price of the Ordinary Shares on August 10, 2022 was \$5.67 per share, and the last reported sale price of the Warrants on August 10, 2022 was \$0.96 per warrant, as reported on Nasdaq.

You should read the Prospectus and any prospectus supplement or amendment carefully before you invest in our securities. Investing in the Company's securities involves risks. See "Risk Factors" beginning on page 12 of the Prospectus.

Neither the SEC nor any state securities commission has approved or disapproved of the securities to be issued under the Prospectus or passed upon the adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense.

The date of this prospectus supplement is August 11, 2022.

Cellebrite DI Ltd. Second Quarter 2022 Results Summary (U.S Dollars in thousands)

	For the three mo		For the six months ended June 30,				
	2022	2021	2022	2021			
	Unaudited	Unaudited	Unaudited	Unaudited			
Revenue	62,573	59,168	124,958	112,451			
Gross profit	49,475	49,100	100,877	94,184			
Gross margin	79.1%	83.0%	80.7%	83.8%			
Operating (loss) income	(5,599)	8,221	(7,545)	12,608			
Operating margin	(8.9)%	13.9%	(6.0)%	11.2%			
Cash flow from operations	(4,073)	13,942	(14,610)	13,818			
•	· · ·						

Cellebrite DI Ltd. Condensed Consolidated Balance Sheets (U.S. Dollars in thousands)

		June 30, 2022		December 31, 2021		
	U	naudited	1	Audited		
Assets						
Current assets	_		_			
Cash and cash equivalents	\$	89,181	\$	145,973		
Marketable securities		32,435				
Short-term deposits		18,394		35,592		
Trade receivables (net of allowance for doubtful accounts of \$1,500 and \$1,040 as of June 30, 2022 and December		66.746		67 505		
31, 2021, respectively) Prepaid expenses and other current assets		66,746 11,665		67,505 12,818		
Contract acquisition costs		4,601		4,813		
Inventories		8,116		6,511		
Total current assets	_		_			
Total Current assets	_	231,138		273,212		
Non-current assets						
Other non-current assets		1,826		1,958		
Marketable securities		25,335				
Deferred tax assets, net		12,038		9,800		
Property and equipment, net		17,775		16,756		
Intangible assets, net		9,901		11,228		
Goodwill	_	26,829	_	26,829		
Total non-current assets		93,704		66,571		
Total assets	\$	324,842	\$	339,783		
Liabilities and shareholders' equity (deficiency)						
Current Liabilities	ተ	2.775	ф	0.546		
Trade payables	\$	3,775	\$	9,546		
Other accounts payable and accrued expenses Deferred revenues		47,453		54,044		
Total current liabilities	_	121,645	_	122,983		
Total current habilities		172,873		186,573		
Long-term liabilities						
Other long term liabilities		6,580		9,537		
Deferred revenues		35,476		36,426		
Restricted Sponsor Shares liability		22,600		44,712		
Price Adjustment Shares liability		37,798		79,404		
Derivative warrant liabilities		25,457		56,478		
Total long-term liabilities	_	127,911	_	226,557		
Total liabilities	\$	300,784	\$	413,130		
Shareholders' equity (deficiency)						
Share capital		*)		*)		
Additional paid-in capital		(141,921)		(153,072)		
Treasury stock, NIS 0.00001 par value; 41,776 ordinary shares		(85)		(85)		
Accumulated other comprehensive income		(1,009)		1,372		
Retained earnings		167,073		78,438		
Total shareholders' equity (deficiency)		24,058		(73,347)		
cyany (acresone))	_	2-1,000		(70,047)		
Total liabilities and shareholders' equity (deficiency)	\$	324,842	\$	339,783		
*) Less than 1 USD						

Cellebrite DI Ltd. Condensed Consolidated Statements of Income (U.S Dollars in thousands, except share and per share data)

	For the three months ended June 30,				For the six months ended June 30,				
	2022		2021		2022		2021		
	1	Unaudited		Unaudited	Unaudited		Unaudited		
Revenue:	ф	26.446	ф	20.050	ф	E0 20E	ф	50.044	
Subscription services	\$	36,446	\$	29,870	\$	70,387	\$	58,844	
Term-license		13,395	_	11,588	_	27,653	_	23,135	
Total subscription		49,841		41,458		98,040		81,979	
Perpetual license and other		4,200		10,382		10,300		18,125	
Professional services		8,532		7,328		16,618	_	12,347	
Total revenue	_	62,573	_	59,168		124,958	_	112,451	
Cost of revenue:									
Subscription services		4,576		2,192		8,112		4,674	
Term-license		178		538		368		895	
Total subscription		4,754		2,730		8,480		5,569	
Perpetual license and other		3,256		1,816		5,498		2,876	
Professional services		5,088		5,522		10,103		9,822	
Total cost of revenue		13,098		10,068		24,081	Ξ	18,267	
Gross profit	\$	49,475	\$	49,100	\$	100,877	\$	94,184	
	.	15,175		13,100	.	100,011	_	5 1,120 1	
Operating expenses:									
Research and development		19,675		15,388		39,251		30,281	
Sales and marketing		24,892		18,509		48,151		35,027	
General and administrative		10,507		6,982		21,020		16,268	
Total operating expenses	\$	55,074	\$	40,879	\$	108,422	\$	81,576	
Operating (loss) income	\$	(5,599)	\$	8,221	\$	(7,545)	\$	12,608	
Financial income, net	Ť	38,466	_	496		94,866	_	862	
Income before tax		32,867	_	8,717	_	87,321	_	13,470	
Tax (income) expense		(330)		921		(1,314)		2,084	
Net income	\$	33,197	\$	7,796	\$	88,635	\$	11,386	
	Ė		Ė	,	Ė		Ė	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
Earnings per share:									
Basic	\$	0.18	\$	0.03	\$	0.47	\$	0.03	
Diluted	\$	0.17	\$	0.02	\$	0.44	\$	0.02	
Weighted average shares outstanding:									
Basic		181,907,435		125,404,745		181,217,005		125,106,697	
Diluted		192,133,157		125,404,745		194,355,966		125,106,697	
Other comprehensive income:									
Unrealized (loss) gain on hedging transactions		(1,757)		120		(2,907)		(1,266)	
Unrealized loss on Marketable securities		(237)		_		(286)		_	
Currency translation adjustments		410		(407)		812		55	
Total other comprehensive loss, net of tax		(1,584)		(287)		(2,381)		(1,211)	
Total other comprehensive income	\$	31,613	\$	7,509	\$	86,254	\$	10,175	
	φ	51,013	Φ	7,503	Ф	00,234	φ	10,175	

Cellebrite DI Ltd. Condensed Consolidated Statements of Cash Flow (U.S Dollars in thousands, except share and per share data)

	For the three months ended June 30,				For the six months ended June 30,				
	2022		2021		2022		2021		
Cash flow from operating activities:	Unaudited	i	Unaudited	_	Unaudited	τ	J naudited		
Cash now from operating activities.									
Net income	\$ 33,1	197	\$ 7,79	6	\$ 88,635	\$	11,386		
Adjustments to reconcile net income to net cash provided by operating activities:									
Share based compensation and RSU's	3,6	505	1,70	3	6,463		3,402		
Amortization of premium, discount and accrued interest on marketable securities	((55)	_		(38)		_		
Depreciation and amortization		257	1,69		4,369		3,180		
Interest income from short term deposits (*)		l37)	(14	_	(199)		(489)		
Deferred income taxes		918)	13	4	(1,842)		(569)		
Remeasurement of derivative warrants	(13,9		_		(31,021)		_		
Remeasurement of Restricted Sponsor Shares liability		506)	_		(22,112)		_		
Remeasurement of Price Adjustment Shares liability	(15,8		_		(41,606)				
(Increase) decrease in trade receivables		765)	7,47		(750)		13,709		
Increase (decrease) in deferred revenue		358	(3,94		1,942		(2,692)		
Decrease (increase) in other non-current assets		166	(2,55		133		(4,308)		
Decrease (Increase) in prepaid expenses and other current assets		180	(3,14		930		(5,158)		
(Increase) decrease in inventories	,	274)	1		(1,621)		(123)		
Decrease in trade payables	(5,4		(23		(5,773)		(294)		
Increase (decrease) in other accounts payable and accrued expenses		922	4,95		(9,163)		(4,570)		
(Decrease) increase in other long-term liabilities		<u> 297</u>)	20	_	(2,957)		344		
Net cash (used in) provided by operating activities	(4,0)73)	13,94	2	(14,610)		13,818		
Cash flows from investing activities:									
Purchases of property and equipment		571)	(1,54	6)	(3,876)		(2,854)		
Investment in marketable securities	(33,9	913)	_		(63,189)				
Proceed from marketable securities	5,1	L72	_		5,172		_		
Assets acquisition	-	_	(3,00	0)	_		(3,000)		
Short term deposits, net (*)	(7	784)	21,72	0	17,397		29,569		
Net cash (used in) provided by investing activities	(31,0)96)	17,17	4	(44,496)		23,715		
Cash flows from financing activities:									
Exercise of options to shares	1,0	060	18	7	4,687		187		
Net cash provided by financing activities	1,0	060	18	7	4,687		187		
Net (decrease) increase in cash and cash equivalents	(34,1	109)	31,30	3	(54,419)		37,720		
Net effect of Currency Translation on cash and cash equivalents		129)	12		(2,373)		(173)		
Cash and cash equivalents at beginning of period	125,7		139,96		145,973		133,846		
Cash and cash equivalents at end of period	\$ 89,1	_	\$ 171,39	_	\$ 89,181	\$	171,393		
Supplemental cash flow information:									
Income taxes paid	2,6	502	2,25	4	3,889		5,661		
Non-cash activities									
Purchase of property and equipment		88	1	9	221		184		
*) Reclassification									